Gyre Therapeutics (GYRE) Intangibles (2010 - 2026)

Gyre Therapeutics (GYRE) has reported Intangibles for 10 consecutive years, with $5.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Intangibles rose 4.75% year-over-year to $5.8 million; the TTM figure through Mar 2026 stood at $5.8 million (up 4.75% YoY), while the FY2025 annual figure was $5.8 million, up 2006.23% from the prior year.
• Intangibles rose to $5.8 million in Q1 2026 per GYRE's latest filing, from $5.8 million in the prior quarter.
• Across five years, Intangibles topped out at $5.8 million in Q1 2026 and bottomed at $184000.0 in Q3 2024.
• Historically, Intangibles has averaged $2.9 million across 5 years, with a median of $2.0 million in 2022.
• Annual changes were most pronounced in 2023 — Intangibles plunged 65.6% — and 2025, when it jumped 2745.92%.
• Gyre Therapeutics' Intangibles stood at $2.0 million in 2022, then slumped by 65.6% to $701000.0 in 2023, then slumped by 61.06% to $273000.0 in 2024, then surged by 2006.23% to $5.8 million in 2025, then advanced by 1.62% to $5.8 million in 2026.
• Business Quant data shows GYRE's Intangibles at $5.8 million in Q1 2026, $5.8 million in Q4 2025, and $4.8 million in Q3 2025.